Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 15/20 | 0.58 |
| ▸ | CNR2 | P34972 | 13/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159142 | 0.96 | CNR1 (0.57) | CNR1CNR2P2RX7ADORA2AADORA1 | |
| SCHEMBL4253583 | 0.89 | CNR1 (0.60) | CNR1CNR2 | |
| SCHEMBL30131489 | 0.83 | P2RX7 (0.58) | CNR1CNR2P2RX7 | |
| SCHEMBL14284345 | 0.81 | CNR1 (0.58) | CNR1CNR2P2RX7 | |
| SCHEMBL5231512 | 0.77 | HCRTR2 (0.49) | CNR1CNR2PIM1PIM3 | |
| SCHEMBL6172165 | 0.76 | GRM4 (0.50) | P2RX7PIM1PIM3 | |
| SCHEMBL4968777 | 0.75 | POLB (0.65) | CNR1CNR2P2RX7 | |
| SCHEMBL5233590 | 0.75 | CNR1 (0.75) | CNR1CNR2 | |
| SCHEMBL27212635 | 0.75 | GRM4 (0.55) | P2RX7PIM1PIM3 | |
| SCHEMBL5239059 | 0.75 | PIM1 (0.49) | PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| CN-101336238-A | Novel bicyclic carbonylaminopyridine-2-carboxamides or 3-bicyclic carbonylaminopyrazine-2-carboxamides | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | CN | disclosed |
| EP-1957478-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| CN-101001840-A | Therapeutic compounds: pyridines as skeletons | ASTRAZENECA AB (SE) | 2007-07-18 | — | — | CN | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| EP-1756060-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005115986-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA2, CNR2 | CNR1 14/4885CNR2 3/4885P2RX7 564/4885 |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | OPRL1, OPRK1, P2RX3 | CNR1 6/4885CNR2 11/4885P2RX7 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.